Aridis reports ar-501 clinical data positive safety data in healthy subjects of a phase 1/2a clinical trial

Aridis reports ar-501 clinical data: positive safety data in healthy subjects of a phase 1/2a clinical trial.aridis pharmaceuticals inc - ar-501 aerosols were well tolerated.aridis pharmaceuticals - "look forward to advancing to phase 2a stage of study evaluating adult cystic fibrosis patients, with results expected in 2h 2021.".aridis pharmaceuticals - no serious adverse events , no grade 3 or grade 4 adverse events reported over 28 day study period for single ascending dose cohort.
ARDS Ratings Summary
ARDS Quant Ranking